Tumor formation was completely abrogated at the vaccine site in hosts with competent NK cell compartment due to the up regulation of Il-15, Ulbp1 NK cell receptor, Killer/Dr5 and Fas/Apo-1 death receptors on the treated cell, thus providing a safety benefit for the combination. The gene discussed is TNFRSF10B; the disease is neoplasm.